We are live on ! Find out more
FOLD

Amicus Therapeutics

Delisted

FOLD was delisted on the 24th of April, 2026.

216 hedge funds and large institutions have $3.86B invested in Amicus Therapeutics in 2023 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 82 increasing their positions, 73 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

132% more call options, than puts

Call options by funds: $11.5M | Put options by funds: $4.95M

17% more capital invested

Capital invested by funds: $3.3B → $3.86B (+$557M)

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

12% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 73

2.67% more ownership

Funds ownership: 105.31%107.98% (+2.7%)

4% less funds holding

Funds holding: 226216 (-10)

22% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 32

Holders
216
Holders Change
-10
Holders Change %
-4.42%
% of All Funds
3.39%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.11%
New
25
Increased
82
Reduced
73
Closed
32
Calls
$11.5M
Puts
$4.95M
Net Calls
+$6.55M
Net Calls Change
+$8.49M
Name Holding Trade Value Shares
Change
Change in
Stake
PA
1
Perceptive Advisors
New York
$347M
ACA
2
Avoro Capital Advisors
New York
$344M +$1.19M +100,000 +0.4%
Vanguard Group
3
Vanguard Group
Pennsylvania
$339M +$1.93M +162,472 +0.6%
BlackRock
4
BlackRock
New York
$262M +$13.8M +1,160,568 +6%
RG
5
Redmile Group
California
$246M +$14.5M +1,220,100 +7%
Janus Henderson Group
6
Janus Henderson Group
United Kingdom
$187M +$15.6M +1,313,153 +10%
JP Morgan Chase
7
JP Morgan Chase
New York
$169M -$3.45M -291,094 -2%
Morgan Stanley
8
Morgan Stanley
New York
$164M -$40.8M -3,440,101 -21%
State Street
9
State Street
Massachusetts
$140M +$574K +48,357 +0.4%
PAI
10
Palo Alto Investors
California
$132M
PAMS
11
Pictet Asset Management (Switzerland)
Switzerland
$119M -$6.44M -542,313 -5%
Wellington Management Group
12
Wellington Management Group
Massachusetts
$98.2M +$3.62M +305,255 +4%
Point72 Asset Management
13
Point72 Asset Management
Connecticut
$87.9M +$56.4M +4,751,772 +211%
Macquarie Group
14
Macquarie Group
Australia
$86.9M -$2.96M -249,054 -3%
Deutsche Bank
15
Deutsche Bank
Germany
$78.6M +$61.1M +5,151,461 +465%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$67.8M +$3M +253,199 +5%
Fiera Capital (Canada)
17
Fiera Capital (Canada)
Quebec, Canada
$62.5M -$1.44M -121,579 -2%
AG
18
Artal Group
Luxembourg
$57.3M +$12.3M +1,036,160 +29%
American Century Companies
19
American Century Companies
Missouri
$49.2M +$46.5M +3,914,613 New
Norges Bank
20
Norges Bank
Norway
$41.3M -$22.3M -1,883,102 -36%
Balyasny Asset Management
21
Balyasny Asset Management
Illinois
$40.5M +$13.1M +1,106,425 +52%
Northern Trust
22
Northern Trust
Illinois
$35.4M +$1.18M +99,488 +4%
Goldman Sachs
23
Goldman Sachs
New York
$35.1M +$10.5M +885,390 +46%
Bank of America
24
Bank of America
North Carolina
$29.9M -$1.44M -121,164 -5%
BC
25
Boxer Capital
California
$29.2M

FOLD Hedge Fund Activity: Q2 2023 in Review

216 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q2 2023, worth a combined $3.86B — up 17% from $3.3B a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of FOLD and 25 opened new positions — a net loss of 7 holders — while 73 trimmed existing stakes and 82 added.

The largest buyer was Deutsche Bank, adding an estimated $61.1M. The largest seller was Morgan Stanley, cutting an estimated $40.8M.

  • 216 institutional investors held Amicus Therapeutics (FOLD) as of Q2 2023, down from 226 in Q1 2023.
  • Funds reported $3.86B of Amicus Therapeutics stock for Q2 2023, up 17% quarter-over-quarter.
  • 25 funds opened new Amicus Therapeutics positions in Q2 2023 and 32 closed out, a net change of -7 holders.
  • The largest Amicus Therapeutics buyer in Q2 2023 was Deutsche Bank, an estimated $61.1M added.
  • The largest Amicus Therapeutics seller in Q2 2023 was Morgan Stanley, an estimated $40.8M sold.

Based on aggregated 13F filings for Q2 2023.